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Abstract
© 2017 American  Chemical  Society.  Solid  lipid  nanoparticles  (SLNs)  are  among the  most
promising nanocarriers to target the blood-brain barrier (BBB) for drug delivery to the central
nervous  system  (CNS).  Encapsulation  of  the  acetylcholinesterase  reactivator,  pralidoxime
chloride (2-PAM), in SLNs appears to be a suitable strategy for protection against poisoning by
organophosphorus  agents  (OPs)  and  postexposure  treatment.  2-PAM-loaded  SLNs  were
developed for  brain  targeting and delivery via  intravenous (iv)  administration.  2-PAM-SLNs
displayed a high 2-PAM encapsulation efficiency (∼90%) and loading capacity (maximum 30.8 ±
1%). Drug-loaded particles had a mean hydrodynamic diameter close to 100 nm and high
negative zeta potential  (-54 to -15 mV).  These properties contribute to improve long-term
stability of 2-PAM-SLNs when stored both at room temperature (22 °C) and at 4 °C, as well as to
longer circulation time in the bloodstream compared to free 2-PAM. Paraoxon-poisoned rats (2 ×
LD 50 ) were treated with 2-PAM-loaded SLNs at a dose of 2-PAM of 5 mg/kg. 2-PAM-SLNs
reactivated 15% of brain AChE activity. Our results confirm the potential use of SLNs loaded with
positively  charged  oximes  as  a  medical  countermeasure  both  for  protection  against  OPs
poisoning and for postexposure treatment.
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